TG Therapeutics Inc. announced the publication of five-year data from the open-label extension of the Phase 3 ULTIMATE I and II studies evaluating BRIUMVI (ublituximab-xiiy) in adults with relapsing forms of multiple sclerosis. The results, published in JAMA Neurology, showed sustained clinical efficacy, low relapse rates, and a consistent safety profile over five years of continuous treatment. The data were based on more than 3,600 participant-years of ublituximab exposure, with over 70% of participants remaining on treatment at year five. No new safety signals emerged during prolonged treatment. The results have already been presented through publication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9655722-en) on February 17, 2026, and is solely responsible for the information contained therein.